New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials

(MedPage Today) -- CHICAGO -- More than 70% of patients with heavily pretreated multiple myeloma had responses to the novel bispecific antibody talquetamab plus subcutaneous daratumumab (Darzalex Faspro), a preliminary trial showed. The higher...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news